Exclusive: Cell and gene therapy CDMO VintaBio emerges onto the scene with $64M and a new CEO

A contract manufacturer is emerging from stealth with cash on hand and a new CEO — and jumping right into the busy cell and gene therapy …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ex­clu­sive: Cell and gene ther­a­py CD­MO VintaBio emerges on­to the scene with $64M and a new CEO